期刊文献+

MMP-9、LMP-1在鼻NK/T细胞淋巴瘤组织中的表达及意义 被引量:3

The Expression and Significance of Matrix Metalloproteinase-9 and Latent Membrane Protein-1 in Nasal NK/T Cell Lymphoma
下载PDF
导出
摘要 目的通过检测鼻NK/T细胞淋巴瘤组织中的基质金属蛋白酶-9(MMP-9)、潜伏膜蛋白-1(LMP-1)蛋白的表达及分布情况,探讨两者间的相互关系,为临床治疗和预后判断提供依据。方法采用免疫组化S-P法检测20例鼻NK/T细胞淋巴瘤组织中MMP-9、LMP-1的表达情况,同时与组织芯片中其他类型淋巴瘤及10例淋巴组织反应性增生进行比较。结果鼻NK/T细胞淋巴瘤组中MMP-9、LMP-1阳性表达率分别为90.0%(18/20)和45.0%(9/20);组织芯片包含的B细胞淋巴瘤组及外周T细胞淋巴瘤组MMP-9的阳性表达率分别为61.1%(11/18)、50.0%(6/12),LMP-1的阳性表达率分别为11.1%(2/18)、25.0%(3/12)。淋巴组织反应性增生组未见LMP-1的阳性表达,MMP-9的阳性表达率为30.0%(3/10)。鼻NK/T细胞淋巴瘤组MMP-9、LMP-1阳性表达率与淋巴组织反应性增生组比较差异有统计学意义(P<0.05),MMP-9与LMP-1表达呈正相关(r=0.327,P<0.05)。结论MMP-9在鼻NK/T细胞淋巴瘤组织中存在高表达,与EB病毒感染关系密切,LMP-1能上调MMP-9表达,可能与鼻NK/T细胞淋巴瘤的高度侵袭性有关。 Objective To detect the expression and distribution of matrix metalloproteinase-9 and latent membrane protein-1 in nasal NK/T cell lymphoma,and to provide evidences for clinical treatment and evaluation of prognosis by investigate the relationship of the both sides. Methods Immunohistochemistry by S-P technique was used to detect the expression of matrix metalloproteinase-9 and latent membrane protein-1 in nasal NK/T cell lymphoma, meanwhile a tissue chip of other type lymphoma and 10 cases of reactive lymphoid hyperplasia were used for relative research. Results The positive expression rate of MMP-9 and LMP-1 in the group of nasal NK/T cell lymphoma was 90.0% (18/20)and 45.0% (9/20), respectively. Tissue chip consist of the group of B-cell lymphoma and T-cell lymphoma . The positive expression rate of MMP-9 and LMP-1 in the group of B-cell lymphoma was 61. 1%(11/18)and 11. 1% (2/18), respectively, while those in 12 cases of T-cell lymphoma was 50. 0% (6/12)and 25.0% (3/12), respectively.There was no positive expression of LMP-1 in reactive lymphoid hyperplasia and the positive expression rate of MMP-9 was 30.0%(3/10), and the positive expression rates between the group of nasal NK/T cell lymphoma and reactive lymphoid hyperplasia had significant difference statistically(P〈0.05). The expression of MMP-9 showed a positive correction with the expression of LMP-1(r=0. 327,P〈0.05). Conclusion MMP-9 is highly expressed in nasal NK/T cell lymphoma which is close correlated with the virus of EB. The induction of MMP-9 by LMP-1 may contribute to the intense invasiveness of nasal NK/T cell lymphoma.
出处 《实用临床医学(江西)》 CAS 2008年第1期1-3,20,F0004,共5页 Practical Clinical Medicine
关键词 鼻肿瘤 NK细胞 淋巴瘤 免疫组织化学 MMP-9 LMP-1 nose neoplasms NK/T-cell lymphoma immunohistochemistry matrix metalloproteinase-9 latent membrane protein-1
  • 相关文献

参考文献11

  • 1Harris N L,Jaffe E S,Diebold J,et al. The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissue: Report of the Clinical Advisory Committee Meeting[J]. Hematol J, 2000,1 (1) : 53-66.
  • 2曹立明,彭瀚涛.基质金属蛋白酶MMP-2,MMP-9与肺癌的侵袭和转移[J].国外医学(生理病理科学与临床分册),2002,22(5):467-469. 被引量:19
  • 3Hanemaaier R, Verheijen J H, Maguire T M, et al. Increased Gelatinase-A and Gelatinase-B Activities in Malignant vs Benign Breast Tumors[J]. Int J Cancer,2000,86(2):204-207.
  • 4杜波,王苹,杜宝东,郭晓峰.MMP-2和MMP-9在喉癌组织中的表达及其与预后的关系[J].吉林大学学报(医学版),2002,28(6):583-586. 被引量:7
  • 5Tsang N M,Chuang C C,Tseng C K,et al. Presence of the Latent Membrane Protein 1 Gene in Nasopharyngeal Swabs trom Patients with Mucosal Recurrent Nasopharyngeal Carcinoma [J]. Cancer,2003,98(11) :2385-2392.
  • 6Tabata Yhibi S,Teramura T,Kuriyama K,et al. Molecular Analysis of Latent Membrane Protein 1 in Patients with Epstein-barr Virus-associated Hemophagocytic Lympho Histiocytosis in Japan[J]. Leuk Lymphoma,2000,38(34) :373-380.
  • 7Weiping C, Neil R C. Epstein-barr Virus Nuclear Antigen 2 and Latent Membrane Protein Independently Transactivate P53 through Induction of NF-Kappa B Activity[J]. J Virol, 1996, 70(7) :4849-4853.
  • 8Jiang W G, Mansel R E. E-cadherin Complex and Its Abnormalities in Human Breast Cancer[J]. Surg Oncol, 2000,9 : 151-171.
  • 9Hazar B,Polat G, Seyrek E, et al. Prognostic Value of Matrix Metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and Non-Hodgkin' s Lymphoma[J]. Int J Clin Pract, 2004,58 (2) : 139-143.
  • 10Bond M,Fabunmi R P,Baker A H,et al. Synergistic Upregulation of Metalloproteinase-9 By Growth Factors and Inflammatory Cytokines: an Absolute Requirement for Transcription Factor NF-kappa B[J]. Febs Lett, 1998,435 ( 1 ) : 29-34.

二级参考文献29

  • 1David E, Kleine R, William G, et al. Matrix metallproteinases and metastasis[J]. Cancer Chemother Pharmacol,1999,43:42-51.
  • 2Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and its regulatory dysfunction in disease[J]. Biological Chemistry Hoppe Seyler, 1995, 376(6):345- 355.
  • 3Sang QX, Birkeda-hansen H, Vanwart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B[J]. Biochim Biophys Acta, 1995, 1251(2): 99-108.
  • 4Stetler-stevenson WG. Matrix metalloproteinase inhibitors, in cancer therapeutics: experimental and clinical agents (ed: Teicher, B) [M].Totowa, NJ: Humana Press Inc. 1997,241- 262.
  • 5Greene J, Wang M, Liu YE, et al. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4[J].J Biol Chem,1996,271 (48) :30375 - 30380.
  • 6Ieng ZS, Guille M. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases[J]. Br J Cancer, 1995,72:575- 579.
  • 7Kleiner D, Stetler-stevenson W. Cancer Chemother Pharmacol, 1999,43(suppl): 42-51.
  • 8Farias E, Ranuncolo S, Cresta C, et al. Plasma metal oproteinase ectivity is enhanced in the ecglobulin fraction of breast and lung cancer patients[J]. Int J Cancer, 2000,89(4):389-394.
  • 9Thomas P, Khokha R, Shepherd FA, et al. Differential expression of MMPs and their inhibitors in non-small cell lung cancer[J]. J Pathol,2000,190(2): 150 - 156.
  • 10Suzuki M, IizasaT, FujisawaT, etal. Expression of matrix metalloproteinases and tissue inhibitor of natrix metalloproteinases in non-small-cell lung cancer[J]. Invasion Metastasis, 98-99, 18 (3):134- 141.

共引文献23

同被引文献23

  • 1钟美佐,黄进,翟晓,刘巍,李建璜,陈方平.MMP-9、MMP-2在非霍奇金淋巴瘤病理组织中的表达及意义[J].现代肿瘤医学,2006,14(2):218-220. 被引量:8
  • 2李治,帅晓明,黄韬.MMP-2、MMP-9在乳腺癌转移中作用的研究[J].华西医学,2006,21(1):43-44. 被引量:17
  • 3关立华,张淑兰.基质金属蛋白酶-26和金属蛋白酶组织抑制剂-4在子宫内膜癌组织中的表达[J].山西医药杂志,2007,36(2):121-125. 被引量:8
  • 4黄振录,莫祥兰,丁志敏.黏膜成熟T细胞和NK细胞淋巴瘤组织中TIMP-2与MMP-9表达及意义[J].山东医药,2007,47(14):49-50. 被引量:2
  • 5Hazar B,Polat G, Sevrek E, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and Non-Hodgkin's lymphoma[J]. Int J Clin Pract, 2004, 58(2): 139-143.
  • 6Ozalp S, Tanir HM, Yalcin OT, et al. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors[J]. Eur J Gynaecol Oncol, 2003,24(5): 417-420.
  • 7Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR [J]. Nucleic Acids Res, 2001, 29(9):e45.
  • 8Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise compurison and statistical analysis of relative expression results in real-time PCR[J]. Nucleic Acids Res, 2002, 30(9): e36.
  • 9La Rocca G, Pucci-Minafra I, Marrazzo A, et al. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera[J]. Br J Cancer, 2004, 90(7): 1414-1421.
  • 10Oberg A Hoyhtya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2,MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1,TIMP-2) in colorectal cancer [J]. Anticancer Res, 2000, 20(2B):1085-1091.

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部